What does P210 BCR-ABL1 mean?
Positive. BCR-ABL1 fusion transcripts (p210) detected. BCR-ABL1/ABL1 quantitative ratio is provided (normalized copy number) Weakly positive. BCR-ABL1 fusion transcripts detected below the limit of quantitation.
What is Philadelphia chromosome test?
This test looks at chromosomes under a microscope to detect structural and/or numerical abnormalities. For example, the Philadelphia chromosome is a small abnormal version of chromosome 22 resulting from the exchange or translocation of material between chromosome 9 and chromosome 22.
What is P210 b3a2 b2a2 major transcript?
There are two major forms of the BCR/ABL fusion gene, involving ABL exon 2, but including different exons of BCR gene. The transcripts b2a2 or b3a2 code for a p210 protein. Another fusion gene leads to the expression of an e1a2 transcript, which codes for a p190 protein.
Where are the BCR and Abl genes located?
Focus Test Summary. The BCR gene is located on chromosome 22, while the Abl gene (a tyrosine kinase) is located on chromosome 9. The t(9;22) results in juxtaposition of these two genes and formation of the Philadelphia chromosome. The product of the fusion gene BCR-ABL codes for a chimeric protein that is a constitutively active tyrosine kinase.
How does the BCR-ABL1 qRT-PCR test work?
The BCR-ABL1 QRT-PCR test quantitatively measures the RNA blood level of BCR-ABL1, a marker for the presence and amount of transcriptionally active Philadelphia chromosome positive leukemia cells.
What is the molecular weight of bcr-abl fusion protein?
This gene encodes for a BCR-ABL fusion protein. Depending on the precise location of fusion, the molecular weight of this protein can range from 185 to 210 kDa. Consequently, the hybrid BCR-ABL fusion protein is referred to as p210 or p185.
Is the BCR-ABL1 quantitation assay dependent on reliable measurement?
The BCR-ABL1 quantitation assay is dependent on reliable measurement of the BCR-ABL1 transcript and allows comparison of BCR-ABL1 levels to MMR. Quantitation of the transcript reflects the proportion of residual leukemia cells in the patient.